Vitamin E in Preventing the Side Effects of Isotretinoin in Former and Current Smokers Who Are Receiving Isotretinoin to Prevent Lung Cancer
Information source: National Cancer Institute (NCI)
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Lung Cancer
Intervention: isotretinoin (Drug); vitamin E (Drug)
Phase: Phase 3
Status: Active, not recruiting
Sponsored by: M.D. Anderson Cancer Center
Official(s) and/or principal investigator(s):
Rodger J. Winn, MD, Study Chair, Affiliation: M.D. Anderson Cancer Center
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the
development or recurrence of cancer. The use of isotretinoin may be an effective way to
prevent lung cancer. Vitamin E may prevent the side effects of isotretinoin therapy.
PURPOSE: Randomized clinical trial to study the effectiveness of vitamin E in preventing the
side effects of isotretinoin in former and current smokers who are receiving isotretinoin to
prevent lung cancer.
Official title: A Randomized Study of the Effect of Alpha-Tocopherol (AT) on 13-Cis-Retinoic Acid (13-cRA) Toxicity in a Preliminary Chemoprevention Trial in Former and Current Smokers
Study design: Prevention, Randomized
OBJECTIVES: I. Determine whether the addition of alpha-tocopherol (AT; vitamin E) to
isotretinoin decreases the incidence of Grade II and higher toxicity of isotretinoin when
administered to former and current smokers. II. Determine the compliance rate of isotretinoin
of smoker and former smokers with or without AT over a six month period. III. Determine the
feasibility of recruiting former and current smokers with or without AT over a six month
period. IV. Determine the effect of isotretinoin administration on serum retinol and
retinol-binding protein levels in these patients.
OUTLINE: This is randomized, placebo controlled study. Patients are stratified by smoking
status (current smoker vs former smoker) and age (less than 50 vs 50 and over). Patients are
randomized to be take alpha-tocopherol (AT) orally and isotretinoin orally daily (arm I) or
isotretinoin orally plus AT placebo orally daily (arm II). Treatment in each arm continues
for 6 months. Patients are followed at 1, 3, 6, and 7 months from start of treatment.
PROJECTED ACCRUAL: There will be 300 patients (150 per arm) accrued into this study over an
estimated 9 months.
Minimum age: 18 Years.
Maximum age: N/A.
DISEASE CHARACTERISTICS: Current smokers with 20+ packs per year history of smoking OR
Former smokers who discontinued smoking 1 year prior to registration (less than 5
cigarettes in the prior year) and had a 20+ packs per year history prior to discontinuing
PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Not specified Life
expectancy: Not specified Hematopoietic: WBC greater than 3,000/mm3 Platelet count greater
than 100,000/mm3 Hepatic: Bilirubin less than 1. 5 mg/dL SGOT less than 40 IU/mL OR SGPT
less than IU/mL Renal: Not specified Other: Fasting triglycerides less than 320 mg/dL No
prior malignancy in the past 5 years except nonmelanomous skin cancer or noninvasive
cervical cancer No history of malabsorption syndrome Not pregnant Effective contraception
required of all fertile persons
PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
isotretinoin Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not
specified Other: No prior warfarin or its derivatives At least 3 months since megadose
vitamin A (greater than 25,000 IU/day) or beta-carotene greater than 30 mg/day or
alpha-tocopherol at least 400 IU daily No concurrent megadose vitamin A (greater than
25,000 IU/day), beta-carotene greater than 30 mg/day, alpha-tocopherol at least 400 IU
daily, or other daily supplements and tonics
Locations and Contacts
Clinical trial summary from the National Cancer Institute's PDQ® database
Last updated: May 23, 2008